Excellent tolerability plus low incidence of GI side effects
Tindamax® is a second-generation nitroimidazole. While chemically related to metronidazole, it has a more favorable pharmacokinetic profile, longer plasma half-life, and significantly reduced incidence of side effects.
Pharmacokinetic profile: plasma half-life1
Figure 1
In bacterial vaginosis
In a large-scale study of tinidazole for treatment of bacterial vaginosis, both oral dosing options (2 g × 2 days and 1 g × 5 days) provided effective therapy with a low incidence of nausea and other GI side effects typically associated with metronidazole therapy.2
| Side effect profile | Tinidazole 1 g qd for 5 days | Tinidazole 2 g qd for 2 days | Placebo | Total |
|---|---|---|---|---|
| Number of participants | 77 | 78 | 80 | 235 |
| Any gastrointestinal symptom(s) | 19 (24.7) | 25 (32.1) | 18 (22.5) | 62 (26.0) |
| Dysgeusia (bad or metallic taste in mouth) | 20 (26.0)* | 31 (39.7)* | 4 (5.0) | 55 (23.4) |
| Headache | 9 (11.7) | 14 (17.9) | 13 (16.3) | 36 (15.3) |
| Nausea | 8 (10.4) | 14 (17.9)† | 6 (7.5) | 28 (11.9) |
| Abdominal discomfort | 7 (9.1) | 4 (5.1) | 6 (7.5) | 17 (7.2) |
| Vulvovaginal discomfort | 7 (9.1) | 7 (9.0) | 2 (2.5) | 16 (6.8) |
| Genital pruritus (female) | 6 (7.8) | 5 (6.4) | 2 (2.5) | 13 (5.5) |
| Fatigue | 1 (1.3) | 4 (5.1) | 6 (7.5) | 11 (4.7) |
| Dizziness | 4 (5.2) | 4 (5.1) | 1 (1.3) | 9 (3.8) |
| Vaginal discharge | 2 (2.6) | 3 (3.8) | 3 (3.8) | 8 (3.4) |
| Urine abnormality | 3 (3.9) | 4 (5.1) | 1 (1.3) | 8 (3.4) |
| Stomach discomfort | 2 (2.6) | 3 (3.8) | 2 (2.5) | 7 (3.0) |
| Vaginal candidiasis | 4 (5.2) | 2 (2.6) | 1 (1.3) | 7 (3.0) |
| Diarrhea | 1 (1.3) | 2 (2.6) | 2 (2.5) | 5 (2.1) |
| Vaginal odor | 1 (1.3) | 1 (1.3) | 3 (3.8) | 5 (2.1) |
|
Adverse events reported in more than 2% of participants, tinidazole treatment of bacterial vaginosis, intent-to-treat population2 Data are n (%). A patient was counted, at most, once per preferred term, system organ class, or any event. * P<0.001 compared with placebo. † P<0.5 compared with placebo. |
Table 1 | |||
In trichomoniasis
Tinidazole also demonstrated excellent tolerability during a study evaluating 2-g × 1-day dosing for trichomoniasis3 and was found to be a "potent and well-tolerated option" vs metronidazole in another TV treatment study.4
Incidence of GI adverse events: Pooled data from 3 comparative studies3,5,6
Figure 2
Simplify dosing and reduce complications
With the convenience of oral treatment, short dosing schedules, and reduced complications from secondary vaginal candidiasis, Tindamax® offers a simple, effective solution to treating bacterial vaginosis and trichomoniasis as well as GI infections.
- Research shows that patients prefer oral therapy vs vaginal creams in the treatment of BV1
- Compared to metronidazole, Tindamax® therapy requires fewer than half the doses required for effective BV treatment2
- Tindamax® targets infection-causing pathogens while sparing protective lactobacilli; this results in a lower risk of secondary vaginal candidiasis, a treatment complication that can increase patient return rates
- Data on file. Mission Pharmacal Company.
- Livengood CH 3rd, Ferris DG, Wiesenfeld HC, Hillier SL, Soper DE, Nyirjesy P, Marrazzo J, Chatwani A, Fine P, Sobel J, Taylor SN, Wood L, Kanalas JJ. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):302-9.
- Manorama HT, Shenoy DR. Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole. J Int Med Res. 1978;6(1):46-9.
- Nanda N, Michel RG, Kurdgelashvili G, Wendel KA. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther. 2006 Feb;4(1):125-35.
- Anjaeyulu R, Gupte SA, Desai DB. Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res. 1977;5(6):438-41.
- Weidenbach A, Leix H. Treatment of trichomonal vaginitis with a single dose of tinidazole. Curr Med Res Opin. 1974;2(3):147-52.
Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).
Clinical Insight
Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»
Beyond BV
Tindamax® may be prescribed for other infections including:
The Mission Pharmacal family of products
Learn more about innovative therapies including...
CitraNatal®Calcium citrate with vital nutrients for mother and baby » Ferralet® 90The iron therapy with biocomplementary absorption » Urocit®-KKidney stone therapy with wax-matrix delivery for slow, sustained release »
